bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer

Andrea Bonetti, Marta Zaninelli, Roberto Leone, Gian Luigi Cetto, Giuseppe Pelosi, Sonia Biolo, Alessandra Menghi, Erminia Manfrin, Franco Bonetti, Quirino Piubello

Research output: Contribution to journalArticle

Abstract

Programmed cell death is an important determinant of the response to chemotherapy. Among the factors controlling this process, a significant role is played by bcl-2 and p53, the expression of which, together with estrogen receptor content and tumor proliferative activity, was investigated by means of immunohistochemistry in 55 advanced breast cancer patients (median age, 60 years; range, 25-71 years). Analysis of bcl-2 expression identified two groups of patients with a significant difference in response rate. A total of 17 patients (31%) responded to chemotherapy (5 had a complete response and 12 had a partial response): 14 of 32 (44%) bcl-2-negative patients (

Original languageEnglish
Pages (from-to)2331-2336
Number of pages6
JournalClinical Cancer Research
Volume4
Issue number10
Publication statusPublished - Oct 1998

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Bonetti, A., Zaninelli, M., Leone, R., Cetto, G. L., Pelosi, G., Biolo, S., Menghi, A., Manfrin, E., Bonetti, F., & Piubello, Q. (1998). bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clinical Cancer Research, 4(10), 2331-2336.